1st Edition
Bayesian Applications in Pharmaceutical Development
Preface
1. Introduction
2. Incorporation of Historical Control Data in Analysis of Clinical Trials
3. Practical considerations for building priors for confirmatory studies
4. The Practice of Prior Elicitation
5. Bayesian examples in preclinical in-vivo research
6. Planning a model-based Bayesian dose response study
7. Novel Designs for Early Phase Drug Combination Trials
8. Executing and Reporting Clinical Trial Simulations: Practical Recommendations for Best Practices
9. Reporting of Bayesian Analyses in Clinical Research: Some Recommendations
10. Handling missing data in clinical trials with Bayesian and Frequentist Approaches
11. Bayesian Applications in Pharmaceutical Development
12. Simulation for Bayesian Adaptive Designs – Step-by-Step Guide for Developing the Necessary R Code
13. Power Priors for Sample Size Determination in the Process Validation Life-Cycle
14. Bayesian Approaches in the Regulation of Medical Products
15. Computational tools
16. Software for Bayesian Computation - An Overview of Some Currently Available Tools
17. Considerations and Bayesian Applications in Pharmaceutical Development for Rare Diseases
18. Extrapolation Process in Pediatric Drug Development and Corresponding Bayesian Implementation for Validating Clinical Efficacy
19. BM- Appendix: A Brief Guide to Bayesian Model Checking
Biography
Dr. Mani Lakshminarayanan is a researcher and statistical consultant with more than 30 years of experience in the pharmaceutical industry. He has published over 50 articles, technical reports, and book chapters besides serving as a referee for several journals. He has a Ph.D. in Statistics from Southern Methodist University, Dallas, Texas and is a Fellow of the American Statistical Association.
Dr. Fanni Natanegara has over 15 years of pharmaceutical experience and is currently Principal Research Scientist and Group Leader for the Early Phase Neuroscience Statistics team at Eli Lilly and Company. She played a key role in the Advanced Analytics team to provide Bayesian education and statistical consultation at Eli Lilly. Dr. Natanegara is the chair of the cross industry-regulatory-academic DIA BSWG to ensure that Bayesian methods are appropriately utilized for design and analysis throughout the drug-development process.
